Form 8-K Kymera Therapeutics, For: Jun 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets
June 25, 2025 4:05 PM EDTBrookline Capital Markets analyst Leah Rush Cann lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $70.00 (from $97.00) while maintaining a Buy rating.
The analyst comments "Conclusions Our estimated revenue for 2025 2027 is being reduced resulting from timing of collaboration revenue from Sanofi. We have... More
Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
June 25, 2025 12:43 PM EDTJefferies analyst Kelly Shi lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $64.00 (from $66.00) while maintaining a Buy rating.
The analyst comments "KYMR announced two updates on parternship: 1) SNY will not advance Ph2 IRAK4 degrader KT-474 in AD/HS and will... More
Stifel says buy Kymera Therapeutics (KYMR) on today's weakness
June 25, 2025 10:32 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR), saying they would buy on today's weaknesses related to the updated on the Sanofi IRAK4 collaboration. Shares of KYMR are down 3.7% currently.
The analyst commented, "We are reiterating our Buy Rating on... More
